| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 35 | 2026 | 297 | 6.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2026 | 1963 | 3.490 |
Why?
|
| Antibodies, Bispecific | 13 | 2025 | 68 | 3.250 |
Why?
|
| Neoplasms | 43 | 2026 | 2906 | 2.970 |
Why?
|
| Antineoplastic Agents | 35 | 2024 | 2214 | 2.840 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2025 | 89 | 2.720 |
Why?
|
| Induction Chemotherapy | 5 | 2026 | 88 | 1.790 |
Why?
|
| Maximum Tolerated Dose | 21 | 2023 | 210 | 1.360 |
Why?
|
| Medical Oncology | 5 | 2023 | 339 | 1.260 |
Why?
|
| Child | 77 | 2026 | 22707 | 1.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2025 | 699 | 1.170 |
Why?
|
| Recurrence | 22 | 2026 | 1138 | 1.120 |
Why?
|
| Pyridines | 8 | 2025 | 609 | 1.070 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1149 | 1.070 |
Why?
|
| Oligopeptides | 4 | 2026 | 267 | 1.070 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 26 | 0.990 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 124 | 0.970 |
Why?
|
| Lymphoma, B-Cell | 6 | 2023 | 140 | 0.940 |
Why?
|
| Antibodies, Monoclonal | 11 | 2018 | 1505 | 0.930 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2024 | 198 | 0.930 |
Why?
|
| Immunotherapy | 6 | 2023 | 666 | 0.870 |
Why?
|
| Child, Preschool | 42 | 2026 | 11853 | 0.810 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2022 | 686 | 0.790 |
Why?
|
| Treatment Outcome | 36 | 2026 | 11772 | 0.780 |
Why?
|
| Humans | 138 | 2026 | 145474 | 0.770 |
Why?
|
| Hodgkin Disease | 3 | 2025 | 171 | 0.770 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 1061 | 0.770 |
Why?
|
| Azacitidine | 4 | 2024 | 157 | 0.740 |
Why?
|
| Leukemia | 6 | 2021 | 246 | 0.740 |
Why?
|
| Etoposide | 7 | 2022 | 168 | 0.730 |
Why?
|
| Adolescent | 49 | 2026 | 22529 | 0.730 |
Why?
|
| Benzamides | 4 | 2021 | 226 | 0.720 |
Why?
|
| Antigens, CD19 | 7 | 2026 | 128 | 0.710 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2025 | 2028 | 0.660 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2018 | 22 | 0.640 |
Why?
|
| T-Lymphocytes | 5 | 2026 | 1996 | 0.620 |
Why?
|
| para-Aminobenzoates | 1 | 2019 | 8 | 0.620 |
Why?
|
| Quinazolines | 3 | 2010 | 266 | 0.600 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2018 | 127 | 0.600 |
Why?
|
| Deoxycytidine | 4 | 2011 | 220 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 67 | 0.590 |
Why?
|
| Prodrugs | 1 | 2019 | 52 | 0.580 |
Why?
|
| Rare Diseases | 2 | 2017 | 116 | 0.580 |
Why?
|
| Infant | 28 | 2026 | 10077 | 0.580 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2021 | 218 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2024 | 981 | 0.580 |
Why?
|
| Brain Stem Neoplasms | 3 | 2017 | 87 | 0.580 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2024 | 72 | 0.570 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2026 | 342 | 0.570 |
Why?
|
| Pyrrolidines | 1 | 2019 | 125 | 0.570 |
Why?
|
| Male | 80 | 2026 | 72842 | 0.560 |
Why?
|
| DNA Methylation | 3 | 2024 | 674 | 0.560 |
Why?
|
| Dasatinib | 2 | 2018 | 58 | 0.550 |
Why?
|
| Female | 79 | 2026 | 78844 | 0.550 |
Why?
|
| Immunoconjugates | 2 | 2025 | 138 | 0.550 |
Why?
|
| Astrocytoma | 3 | 2017 | 130 | 0.530 |
Why?
|
| Piperidines | 2 | 2010 | 222 | 0.520 |
Why?
|
| Poverty | 1 | 2021 | 526 | 0.500 |
Why?
|
| Glioma | 5 | 2022 | 429 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 992 | 0.460 |
Why?
|
| Young Adult | 34 | 2026 | 14218 | 0.450 |
Why?
|
| Administration, Oral | 9 | 2019 | 866 | 0.450 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 239 | 0.450 |
Why?
|
| Biomedical Research | 3 | 2017 | 717 | 0.450 |
Why?
|
| Sirolimus | 2 | 2016 | 280 | 0.450 |
Why?
|
| Sulfonamides | 5 | 2020 | 583 | 0.440 |
Why?
|
| Glycine | 3 | 2025 | 186 | 0.430 |
Why?
|
| Lymphoma | 2 | 2023 | 237 | 0.410 |
Why?
|
| Camptothecin | 3 | 2017 | 138 | 0.410 |
Why?
|
| Adult | 50 | 2025 | 40777 | 0.410 |
Why?
|
| Follow-Up Studies | 16 | 2025 | 5423 | 0.410 |
Why?
|
| Nausea | 3 | 2009 | 112 | 0.410 |
Why?
|
| Drug Administration Schedule | 10 | 2017 | 782 | 0.390 |
Why?
|
| Fluorouracil | 4 | 2012 | 231 | 0.380 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2010 | 64 | 0.380 |
Why?
|
| Arsenicals | 1 | 2013 | 28 | 0.380 |
Why?
|
| Oxides | 1 | 2013 | 47 | 0.380 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2024 | 141 | 0.370 |
Why?
|
| Prognosis | 14 | 2024 | 4316 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 5 | 2021 | 439 | 0.360 |
Why?
|
| DNA Damage | 5 | 2023 | 437 | 0.360 |
Why?
|
| Disease-Free Survival | 8 | 2024 | 767 | 0.360 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 2010 | 6 | 0.350 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2024 | 454 | 0.340 |
Why?
|
| Remission Induction | 4 | 2026 | 307 | 0.330 |
Why?
|
| Vomiting | 2 | 2009 | 131 | 0.330 |
Why?
|
| Neuroblastoma | 2 | 2023 | 174 | 0.330 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2010 | 24 | 0.330 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1321 | 0.320 |
Why?
|
| Doxorubicin | 5 | 2025 | 401 | 0.320 |
Why?
|
| Asparaginase | 3 | 2026 | 32 | 0.320 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 344 | 0.300 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2023 | 258 | 0.300 |
Why?
|
| Infusions, Intravenous | 4 | 2019 | 428 | 0.300 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 270 | 0.300 |
Why?
|
| Aged | 28 | 2025 | 26153 | 0.290 |
Why?
|
| Leukemia, B-Cell | 2 | 2021 | 12 | 0.290 |
Why?
|
| Everolimus | 2 | 2020 | 112 | 0.290 |
Why?
|
| Carboplatin | 2 | 2009 | 162 | 0.290 |
Why?
|
| Pediatrics | 3 | 2008 | 1121 | 0.280 |
Why?
|
| Arabinonucleosides | 2 | 2022 | 8 | 0.280 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2018 | 50 | 0.280 |
Why?
|
| Boronic Acids | 1 | 2008 | 36 | 0.280 |
Why?
|
| Morpholines | 1 | 2009 | 130 | 0.270 |
Why?
|
| Purine Nucleosides | 1 | 2007 | 4 | 0.270 |
Why?
|
| Farnesyltranstransferase | 1 | 2007 | 21 | 0.270 |
Why?
|
| Burkitt Lymphoma | 2 | 2023 | 61 | 0.270 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2007 | 12 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 881 | 0.260 |
Why?
|
| Middle Aged | 29 | 2025 | 36215 | 0.260 |
Why?
|
| Pyrazines | 1 | 2008 | 94 | 0.260 |
Why?
|
| Epigenesis, Genetic | 3 | 2024 | 679 | 0.260 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2025 | 72 | 0.250 |
Why?
|
| Survival Rate | 7 | 2024 | 2090 | 0.250 |
Why?
|
| Pyrimidinones | 1 | 2007 | 125 | 0.250 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 1266 | 0.250 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2020 | 165 | 0.240 |
Why?
|
| Cytarabine | 4 | 2020 | 66 | 0.240 |
Why?
|
| Ethics, Medical | 1 | 2006 | 90 | 0.230 |
Why?
|
| Vincristine | 3 | 2021 | 142 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2014 | 238 | 0.230 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 649 | 0.230 |
Why?
|
| Cisplatin | 1 | 2007 | 345 | 0.230 |
Why?
|
| Philadelphia Chromosome | 2 | 2024 | 18 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2024 | 969 | 0.230 |
Why?
|
| Chondrosarcoma | 1 | 2025 | 17 | 0.220 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2024 | 74 | 0.220 |
Why?
|
| Craniopharyngioma | 2 | 2017 | 77 | 0.220 |
Why?
|
| Methotrexate | 2 | 2020 | 233 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2026 | 673 | 0.210 |
Why?
|
| Pyrazoles | 1 | 2008 | 517 | 0.210 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 143 | 0.210 |
Why?
|
| Neuropilin-1 | 2 | 2014 | 8 | 0.210 |
Why?
|
| Prospective Studies | 10 | 2024 | 8057 | 0.200 |
Why?
|
| Anesthetics, Intravenous | 1 | 2024 | 69 | 0.200 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 56 | 0.200 |
Why?
|
| Propofol | 1 | 2024 | 85 | 0.190 |
Why?
|
| Spinal Neoplasms | 1 | 2003 | 37 | 0.190 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2021 | 51 | 0.190 |
Why?
|
| Drug Discovery | 2 | 2015 | 153 | 0.190 |
Why?
|
| Plant Nectar | 1 | 2022 | 8 | 0.190 |
Why?
|
| Nucleosides | 1 | 2022 | 25 | 0.190 |
Why?
|
| Bone Neoplasms | 1 | 2025 | 259 | 0.180 |
Why?
|
| Drug Design | 2 | 2017 | 175 | 0.180 |
Why?
|
| Osteosarcoma | 1 | 2003 | 82 | 0.180 |
Why?
|
| Cystectomy | 1 | 2022 | 42 | 0.180 |
Why?
|
| Drug Delivery Systems | 3 | 2015 | 381 | 0.180 |
Why?
|
| Neutropenia | 4 | 2017 | 154 | 0.180 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 8333 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 440 | 0.180 |
Why?
|
| Capecitabine | 3 | 2011 | 56 | 0.170 |
Why?
|
| Glycolipids | 1 | 2021 | 53 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2022 | 84 | 0.170 |
Why?
|
| Artificial Gene Fusion | 1 | 2000 | 3 | 0.170 |
Why?
|
| Area Under Curve | 4 | 2009 | 331 | 0.160 |
Why?
|
| Proto-Oncogenes | 1 | 2000 | 28 | 0.160 |
Why?
|
| Vaping | 1 | 2022 | 74 | 0.160 |
Why?
|
| Hematology | 1 | 2001 | 21 | 0.160 |
Why?
|
| Carbazoles | 1 | 2021 | 53 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 230 | 0.160 |
Why?
|
| Bone Marrow | 2 | 2019 | 306 | 0.160 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 3 | 0.160 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 110 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 296 | 0.160 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2021 | 62 | 0.160 |
Why?
|
| Acute Disease | 4 | 2023 | 1036 | 0.160 |
Why?
|
| Weight Reduction Programs | 1 | 2022 | 140 | 0.160 |
Why?
|
| Hospice Care | 1 | 2023 | 227 | 0.150 |
Why?
|
| Mindfulness | 1 | 2022 | 136 | 0.150 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 1480 | 0.150 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 41 | 0.150 |
Why?
|
| Cell Lineage | 1 | 2021 | 377 | 0.150 |
Why?
|
| United States | 10 | 2024 | 16098 | 0.150 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2020 | 280 | 0.150 |
Why?
|
| Cytokines | 3 | 2017 | 2067 | 0.150 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 41 | 0.140 |
Why?
|
| Cohort Studies | 9 | 2022 | 6013 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 561 | 0.140 |
Why?
|
| Survivors | 1 | 2022 | 523 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2018 | 18 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2002 | 1734 | 0.140 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 418 | 0.140 |
Why?
|
| Mutation | 4 | 2025 | 4075 | 0.140 |
Why?
|
| Fetal Blood | 1 | 2000 | 327 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 93 | 0.140 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 108 | 0.130 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 77 | 0.130 |
Why?
|
| Melanoma | 3 | 2017 | 759 | 0.130 |
Why?
|
| Daunorubicin | 1 | 2017 | 25 | 0.130 |
Why?
|
| Single-Blind Method | 2 | 2016 | 318 | 0.130 |
Why?
|
| Cyst Fluid | 1 | 2017 | 20 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 131 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 413 | 0.130 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2017 | 31 | 0.130 |
Why?
|
| United States Food and Drug Administration | 3 | 2023 | 208 | 0.130 |
Why?
|
| Ipilimumab | 1 | 2017 | 40 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 106 | 0.130 |
Why?
|
| Valine | 1 | 2017 | 83 | 0.130 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 23 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2010 | 103 | 0.130 |
Why?
|
| Dexamethasone | 3 | 2020 | 365 | 0.130 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 78 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 2009 | 441 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 23 | 0.120 |
Why?
|
| Carbolines | 1 | 2017 | 35 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 189 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2001 | 354 | 0.120 |
Why?
|
| Age Factors | 4 | 2018 | 3342 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2017 | 146 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2000 | 318 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2021 | 337 | 0.120 |
Why?
|
| Weight Loss | 1 | 2022 | 858 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2009 | 177 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 624 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 1329 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2010 | 552 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2017 | 246 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 534 | 0.110 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 190 | 0.110 |
Why?
|
| EGF Family of Proteins | 1 | 2015 | 17 | 0.110 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 16 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2015 | 17 | 0.110 |
Why?
|
| Parents | 1 | 2024 | 1403 | 0.110 |
Why?
|
| Paclitaxel | 2 | 2014 | 257 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 48 | 0.110 |
Why?
|
| Bortezomib | 2 | 2020 | 54 | 0.110 |
Why?
|
| RNA, Messenger | 5 | 2017 | 2803 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2015 | 92 | 0.110 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2014 | 3 | 0.100 |
Why?
|
| Sarcoma, Myeloid | 1 | 2014 | 4 | 0.100 |
Why?
|
| Cetuximab | 2 | 2017 | 111 | 0.100 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 69 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 68 | 0.100 |
Why?
|
| Disease Progression | 4 | 2021 | 2864 | 0.100 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 71 | 0.100 |
Why?
|
| Apoptosis | 4 | 2010 | 2440 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2014 | 354 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2015 | 635 | 0.100 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 1471 | 0.100 |
Why?
|
| Diphenylamine | 1 | 2013 | 7 | 0.100 |
Why?
|
| Tissue Distribution | 2 | 2013 | 335 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1374 | 0.100 |
Why?
|
| Sulfones | 1 | 2014 | 127 | 0.100 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 29 | 0.100 |
Why?
|
| Models, Biological | 3 | 2025 | 1764 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2013 | 37 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 431 | 0.100 |
Why?
|
| Research Design | 3 | 2024 | 1137 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 1246 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 298 | 0.090 |
Why?
|
| Adenine Nucleotides | 1 | 2012 | 21 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 177 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 171 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 1101 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 485 | 0.090 |
Why?
|
| Macrophage Activation | 1 | 2013 | 181 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 820 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 310 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1747 | 0.090 |
Why?
|
| Dioxoles | 1 | 2011 | 9 | 0.090 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2022 | 1891 | 0.090 |
Why?
|
| Fatigue | 3 | 2009 | 364 | 0.090 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 1767 | 0.080 |
Why?
|
| HL-60 Cells | 1 | 2010 | 30 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 886 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 90 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 49 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 54 | 0.080 |
Why?
|
| Glucuronidase | 2 | 2008 | 27 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 409 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 849 | 0.080 |
Why?
|
| Estrenes | 1 | 2010 | 13 | 0.080 |
Why?
|
| Graft vs Host Disease | 2 | 2010 | 279 | 0.080 |
Why?
|
| Anemia | 2 | 2009 | 191 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 33 | 0.080 |
Why?
|
| Oligosaccharides | 2 | 2008 | 60 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 86 | 0.080 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2021 | 18 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 875 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2021 | 165 | 0.080 |
Why?
|
| Risk Factors | 3 | 2024 | 10885 | 0.070 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 31 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 88 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2008 | 376 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2011 | 168 | 0.070 |
Why?
|
| Ondansetron | 1 | 2009 | 20 | 0.070 |
Why?
|
| Hydrocortisone | 2 | 2022 | 298 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 115 | 0.070 |
Why?
|
| Celecoxib | 1 | 2008 | 42 | 0.070 |
Why?
|
| Placebos | 1 | 2009 | 193 | 0.070 |
Why?
|
| Sulindac | 1 | 2008 | 16 | 0.070 |
Why?
|
| Angiogenic Proteins | 1 | 2008 | 15 | 0.070 |
Why?
|
| Hepatoblastoma | 1 | 2009 | 52 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 112 | 0.070 |
Why?
|
| Plateletpheresis | 1 | 2008 | 28 | 0.070 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2008 | 28 | 0.070 |
Why?
|
| Mice | 7 | 2023 | 18329 | 0.070 |
Why?
|
| Prednisone | 2 | 2020 | 224 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 286 | 0.070 |
Why?
|
| Dibenzocycloheptenes | 1 | 2007 | 5 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 193 | 0.070 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2008 | 70 | 0.070 |
Why?
|
| Animals | 9 | 2023 | 38030 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2010 | 2507 | 0.070 |
Why?
|
| Quality of Life | 2 | 2015 | 3204 | 0.070 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2007 | 25 | 0.070 |
Why?
|
| Rhabdoid Tumor | 1 | 2009 | 102 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 123 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2010 | 598 | 0.060 |
Why?
|
| Cell Survival | 1 | 2010 | 1100 | 0.060 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 18 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2022 | 1111 | 0.060 |
Why?
|
| DNA Repair Enzymes | 1 | 2007 | 29 | 0.060 |
Why?
|
| Food | 1 | 2008 | 150 | 0.060 |
Why?
|
| Incidence | 2 | 2024 | 2923 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 74 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2007 | 100 | 0.060 |
Why?
|
| Lactams, Macrocyclic | 1 | 2007 | 51 | 0.060 |
Why?
|
| Benzoquinones | 1 | 2007 | 46 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2008 | 189 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 307 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 934 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 5 | 0.060 |
Why?
|
| Fasting | 1 | 2008 | 279 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 204 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 261 | 0.060 |
Why?
|
| Microarray Analysis | 2 | 2017 | 116 | 0.060 |
Why?
|
| Retreatment | 2 | 2016 | 79 | 0.060 |
Why?
|
| Flow Cytometry | 5 | 2014 | 1162 | 0.060 |
Why?
|
| Estradiol | 1 | 2010 | 515 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 29 | 0.060 |
Why?
|
| Risk | 1 | 2008 | 919 | 0.060 |
Why?
|
| Genotype | 3 | 2016 | 1852 | 0.060 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2017 | 48 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2025 | 34 | 0.060 |
Why?
|
| Vinblastine | 1 | 2025 | 75 | 0.050 |
Why?
|
| Histocompatibility Testing | 2 | 2005 | 123 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2023 | 17291 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 321 | 0.050 |
Why?
|
| Time Factors | 4 | 2019 | 7123 | 0.050 |
Why?
|
| DNA Primers | 2 | 2006 | 505 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 231 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2014 | 630 | 0.050 |
Why?
|
| Florida | 1 | 2024 | 117 | 0.050 |
Why?
|
| Blood Preservation | 1 | 2008 | 346 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2009 | 2062 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2024 | 155 | 0.050 |
Why?
|
| Caregivers | 2 | 2023 | 1073 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2007 | 353 | 0.050 |
Why?
|
| Survival | 1 | 2003 | 38 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2003 | 42 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 68 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 82 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2003 | 82 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 212 | 0.050 |
Why?
|
| Biometry | 1 | 2022 | 66 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2005 | 420 | 0.050 |
Why?
|
| Morbidity | 1 | 2003 | 322 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 65 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 75 | 0.040 |
Why?
|
| Gangliosides | 1 | 2021 | 23 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 69 | 0.040 |
Why?
|
| Base Sequence | 2 | 2006 | 2170 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2002 | 234 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2016 | 140 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 133 | 0.040 |
Why?
|
| Smokers | 1 | 2022 | 138 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 11 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2022 | 288 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2002 | 193 | 0.040 |
Why?
|
| Furans | 1 | 2021 | 26 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2023 | 282 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 163 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2001 | 62 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 222 | 0.040 |
Why?
|
| Piperazines | 1 | 2023 | 375 | 0.040 |
Why?
|
| Bevacizumab | 2 | 2014 | 168 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1476 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2664 | 0.040 |
Why?
|
| Seizures | 1 | 2024 | 483 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2020 | 15 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 119 | 0.040 |
Why?
|
| Antigens | 1 | 2001 | 348 | 0.040 |
Why?
|
| Certification | 1 | 2001 | 119 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 4295 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 324 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2018 | 15 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3623 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2021 | 195 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2024 | 5216 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2022 | 296 | 0.040 |
Why?
|
| Microsomes, Liver | 1 | 2018 | 85 | 0.040 |
Why?
|
| Midazolam | 1 | 2018 | 73 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 172 | 0.030 |
Why?
|
| Sepsis | 1 | 2024 | 664 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 94 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2018 | 224 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2018 | 405 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 121 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 56 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 2 | 2008 | 53 | 0.030 |
Why?
|
| Benzylamines | 1 | 2017 | 44 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2023 | 1808 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2017 | 72 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2006 | 3747 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2017 | 91 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 266 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1164 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 18 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2001 | 943 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 749 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2016 | 39 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2016 | 65 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2022 | 992 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2001 | 562 | 0.030 |
Why?
|
| Cognition | 1 | 2024 | 1266 | 0.030 |
Why?
|
| Amphiregulin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 210 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 119 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 129 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2018 | 4148 | 0.030 |
Why?
|
| Palliative Care | 1 | 2023 | 1020 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1716 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 141 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2008 | 1707 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3904 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 738 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2014 | 256 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 3542 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2015 | 6447 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 65 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2009 | 2046 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2769 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2016 | 401 | 0.020 |
Why?
|
| Leucovorin | 1 | 2012 | 98 | 0.020 |
Why?
|
| Phenotype | 1 | 2000 | 3155 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 5904 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 381 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 847 | 0.020 |
Why?
|
| Safety | 1 | 2014 | 358 | 0.020 |
Why?
|
| Research | 1 | 2015 | 430 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1443 | 0.020 |
Why?
|
| Phosphotransferases | 1 | 2010 | 26 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2010 | 23 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2014 | 530 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1454 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 6066 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2009 | 10 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
|
| Papilloma | 1 | 2009 | 49 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 83 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 5983 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2930 | 0.020 |
Why?
|
| Alopecia | 1 | 2009 | 37 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 74 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 53 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 28 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 282 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2009 | 42 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 191 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 546 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 458 | 0.020 |
Why?
|
| Maximum Allowable Concentration | 1 | 2008 | 16 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2008 | 85 | 0.020 |
Why?
|
| Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 3116 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 21 | 0.020 |
Why?
|
| Platelet Factor 4 | 1 | 2008 | 36 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 83 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 177 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 117 | 0.020 |
Why?
|
| Taxoids | 1 | 2008 | 114 | 0.020 |
Why?
|
| DNA Repair | 1 | 2009 | 254 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 174 | 0.020 |
Why?
|
| ras Proteins | 1 | 2008 | 150 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 407 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 254 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 175 | 0.020 |
Why?
|
| Thymidine | 1 | 2006 | 60 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 21 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 158 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2006 | 29 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 420 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2008 | 251 | 0.020 |
Why?
|
| Heparin | 1 | 2008 | 247 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2013 | 525 | 0.010 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2006 | 39 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2007 | 202 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 592 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2008 | 223 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 194 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 360 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 221 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 474 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 574 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2006 | 188 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2006 | 288 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 572 | 0.010 |
Why?
|
| Monocytes | 1 | 2008 | 539 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 977 | 0.010 |
Why?
|
| Indoles | 1 | 2008 | 507 | 0.010 |
Why?
|
| Yolk Sac | 1 | 2002 | 5 | 0.010 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2002 | 30 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 2002 | 57 | 0.010 |
Why?
|
| E2F2 Transcription Factor | 1 | 2001 | 14 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1547 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 77 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2001 | 48 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2001 | 65 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2001 | 68 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1997 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 5584 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2188 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 756 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 376 | 0.010 |
Why?
|
| Spleen | 1 | 2001 | 508 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 1179 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 503 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 435 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 866 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2002 | 910 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 3124 | 0.010 |
Why?
|